PREVALENCIA DE SUICÍdio EN TORSUS DE CÓCOIN CONSUMIDORES ACCESANDO SERVICOS DE SAÚDE: UNA RESEÑA SISTEMÁTICA Y METÁLISA

Milton Moçambique, Aline Hoffmann, Vinicius S. Roglio, Felix H.P. Kessler, Carla Dalbosco, Jaqueline B. Schuch, Flavio Pechansky

INTRODUCCIÓN

Cada año, alrededor de 800,000 personas mueren por suicidio, lo que es equivalente a una muerte cada 40 segundos. La evidencia sugiere que para cada adulto que muere por suicidio, más de 20 otras personas pueden haber intentado el suicidio.1,2 El índice mundial de suicidio es estimado en 10,5 por 100,000 habitantes, lo que representa alrededor de 1,4% del total de muertes en el mundo, lo que lo hace el 18º causante de muerte mundial.3

El suicidio es una prevalencia asociada con varios factores de riesgo, como biológicos, psicológicos, sociales, ambientales y culturales. Algunos de estos factores incluyen factores genéticos, trauma, historial de abuso o negligencia, déficits cognitivos, problemas de salud, discriminación, desequilibrio emocional, rechazo, sentimientos de fracaso o impotencia, dolor crónico, etc.4,7 Otros factores de riesgo incluyen SAs y sus asociaciones con el uso de alcohol y otros fármacos.8,9 Aunque algunas teorías han sido desarrolladas para explicar el comportamiento suicida, la teoría de la interacción entre vulnerabilidades adquiridas (conditioned y/or learned) y factores de estrés es la más completa; explica el pensamiento suicida como la interacción de los factores de riesgo mencionados arriba.9,10

El fenómeno del suicidio comprende una serie de comportamientos: pensamiento suicida (suicidio), intento suicida (SA), y suicidio por sí mismo.2,3 El pensamiento suicida (SI) involucra un amplio rango de pensamientos: la intención de morir o el deseo de auto-destrucción, con o sin un plan de acción.5 A SA es un comportamiento potencialmente perjudicial con un salida no-fatal acompañada de evidencia de que: el individuo intencionalmente quiso matarse pero falló y fue rescatado, el intento fue frustrado o el individuo cambió de idea.6 El suicidio, por otro lado, se refiere a la acción de deliberadamente matarse a sí mismo o el auto-suicidio.7,8

CONCLUSIONES

El consumo de cocaína se puede considerar un factor de riesgo para el comportamiento suicida, y la prevención y detección de los comportamientos suicidios tempranos es clave para facilitar el tratamiento adecuado.4,9,10

PALABRAS CLAVE: Suicidio; cocaína; adicción; trastornos de uso de sustancias
used, and the degree of consumption are also contributing factors to suicide-related outcomes. SI seems to be relatively higher among cocaine users. Studies indicate that the prevalence of cocaine use in the days prior to suicide is around 9 to 20%.\(^{11-13}\) Indeed, predicting SAs is a critical element in exacerbated suicide risk – as well as a modifiable factor.

Studies in Brazil indicate that suicidal behaviors are frequent among crack users.\(^{14,15}\) Worldwide, there is still a lack of more robust analysis that combines results from different studies on suicidal behavior, especially among users of cocaine and its derivatives.\(^{4}\) The information must be gathered, organized, and analyzed, considering the essential aspects of suicide in this population. Thus, through a systematic review and meta-analysis, this study aimed to estimate the prevalence of SI and SA among users of cocaine and its derivatives who seek health services.

Methods

This systematic review followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)\(^{16}\) and the Cochrane Handbook\(^{17}\); it was approved in the PROSPERO platform (no. CRD42020142057).

The research strategy included MeSH terms, in addition to the conventional terms: (suicide[mh] OR suicid* [tw]) AND (Cocaine[mh] OR Cocaine[w] OR Cocaine-Related Disorders[mh] OR Cocaine Smoking[mh] OR Crack Smoking[tw]). The search covered articles published in the PubMed/MEDLINE, Scopus, Embase, PsycINFO, and LILACS electronic databases, including searching in other literature sources (the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Catálogo de Teses e Dissertações, the Sucupira Platform, and Google Scholar).

The search was performed on January 10, 2021, and studies published up to this date were included in the systematic review. The initial selection of articles was based on title and abstract reading by two authors (MM and AH) separately. A third author (CD) was consulted when there was a need to evaluate conflicting articles.

Eligibility criteria

The inclusion criteria were observational (retrospective or prospective), case-control, and/or cross-sectional reports that contained samples of cocaine users aged over 14 years who were assessed in health facilities or were in treatment. There were no restrictions on sex, education level, language, or year of publication. We excluded community and household studies, or those with indigenous or prison populations who did not have access to health services. Studies with insufficient or overlapping data, or those that did not discriminate the outcome (SI or SA), qualitative studies, conference abstracts, and review articles (systematic or not, with or without meta-analysis) were excluded. Articles in which the sample used cocaine in addition to other drugs were also excluded, since there was a chance of a confounding bias in the outcomes.

Data extraction and quality assessment of the studies

After article selection, two authors (MM and AH) extracted the data independently. The full texts of the eligible studies were reviewed, and the following data were extracted when possible: authors, year of publication, the sample’s country of origin, age, sex, and characteristics (treatment regimen, multicenter study or not, study period, treatment-seeking), and the outcome (no suicidality, SI, and SA).

The quality of the included studies and the risk of bias were assessed using the Newcastle-Ottawa Statement.\(^{18}\) This scale provides a checklist of items to verify the risk of bias in included studies, scoring a maximum of nine points for the following domains: selection, comparability, exposure, and outcome. In this review, studies with seven points or more were considered high quality, while the others were considered low quality.

Statistical analysis

The synthesis of the studies included in this meta-analysis was structured according to SI and SA prevalence among cocaine users seen in health services, which are presented as forest plots. Variance estimation for the random-effects model was performed using the inverse method; logit transformation was used to analyze group prevalence data and estimate 95% confidence intervals (95%CI). Heterogeneity was assessed with the chi-square test,\(^{19}\) the I-square (I\(^2\)) test, and the Higgins test,\(^{20}\) using the restricted maximum likelihood method to estimate variance. Subgroup analyses were conducted to investigate sources of heterogeneity, including a meta-regression approach with the proportion of men and the mean age. Publication bias was investigated using Egger’s regression test and a funnel plot analysis. All analyses were conducted in R version 3.6.1 and the meta 4.9-72 and metafor 2.1-0 packages.\(^{21}\)

Results

Study selection

The electronic database search yielded 3,476 articles according to the above-described inclusion criteria. Rayyan\(^{22}\) software was used as a reference manager. First, all duplicate articles were removed (n=1,793). The remaining studies were evaluated for design, population, and the outcomes of interest. After reading the title and abstract, another 1,543 articles were excluded for not meeting the outcome or inclusion criteria.

The remaining 140 articles were independently read in full by two authors (MM and AH). At this stage, a third reviewer (CD) was requested to review eight controversial articles. Subsequently, 120 articles were excluded from the meta-analysis for the following reasons: 62 did not present the expected outcome; four were duplicates;
29 did not fulfill all the inclusion criteria (design, population, age); 15 were conference abstracts; one did not discriminate between SI and SA; and four involved the same (or part of the same) sample as previously included studies. In five studies, the data necessary for analysis could not be extracted; the authors of these studies were contacted by e-mail, but none replied. Thus, only 20 articles met the pre-established inclusion criteria and were included in the systematic review. Figure 1 is a flowchart of the article inclusion process.

Characteristics of the included studies

All 20 studies were cross-sectional. Twelve were conducted in the United States, four in Brazil, two in Spain, one in Argentina, and one in Chile. The age of the participants ranged from 14 to 65 years. Most studies included both men and women and did not distinguish between SI and SA in the risk analysis. Some samples also included individuals in different categories of care (inpatient, outpatient, or both). The characteristics of these studies are summarized in Table 1.

Quality evaluation

The quality of the studies was assessed using the Newcastle-Ottawa Statement with some modifications. Fifteen studies were good quality and the other five were low quality (Table 1).

Prevalence of suicidal ideation among users of cocaine and its derivatives (meta-analysis)

A meta-analysis based on ten studies was conducted to assess the SI outcome, finding a combined SI prevalence of 43.59% (95%CI 30.61-57.51) (Figure 2). This result showed high heterogeneity (I² = 95%; Q = 186.72; df = 9, p < 0.01).

Prevalence of suicide attempts in users of cocaine and its derivatives (meta-analysis)

A separate meta-analysis of 12 studies was conducted to assess the SA outcome. The combined SA prevalence was 27.71% (95%CI 21.63-34.73) (Figure 3). There was also high heterogeneity among the studies for this result (I² = 93%; Q = 152.231; degrees of freedom [df] = 11, p < 0.01).

Subgroup analysis

Due to the critical heterogeneity among the studies regarding the SI and SA outcomes, subgroup analyses were performed to identify possible sources of heterogeneity.
Table 1 Characteristics of the included studies

| Author          | Country | Mean age (years) | Sex          | Characteristics of the sample/diagnosis                                      | Total users | NS | SI | SA | NOS |
|-----------------|---------|------------------|--------------|-----------------------------------------------------------------------------|-------------|----|----|----|-----|
| Lowenstein23     | United States | 27.0             | Both         | Outpatient and inpatient, not multicentric, diagnostic criteria not described | 115         | 97 | 18 | 5  |      |
| Rich24           | United States | 29.0             | Both         | Outpatient, not multicentric, diagnostic criteria not described             | 123         | 99 |    |    | 24  |
| Salloum25        | United States | 33.0             | Both         | Outpatient, not multicentric, DSM-III                                    | 25          | 3  | 22 |    | 6   |
| Dhossche26       | United States | 33.9             | Both         | Outpatient, not multicentric, diagnostic criteria not described             | 112         | 86 |    |    | 26  |
| Roy27            | United States | 41.4             | Both         | Veteran outpatient, not multicentric, DSM-IV                               | 214         | 130| 84 |    |     |
| Garlow28         | United States | 39.3             | Both         | Outpatient, not multicentric, DSM-IV                                      | 548         | 326| 222|    | 8   |
| Perez29          | Chile     | N/A              | Both         | Outpatient, not multicentric, diagnostic criteria not described           | 61          | 28 | 30 | 14 | 3   |
| Cottler30        | United States | 32.2             | Both         | Inpatient and outpatient, multicentric, diagnosis criteria not described  | 685         | 319| 367|    | 7   |
| Ilgen31          | United States | 32.8             | Both         | Outpatient and inpatient, not multicentric, diagnostic criteria not described | 2,492       |    | 692|    | 7   |
| Copersino42      | United States | 31.0             | Female       | Inpatient, not multicentric, DSM-IV-TR                                    | 25          | 21 | 27 | 14 | 3   |
| Zubaran32        | Brazil    | 22.8             | Both         | Inpatient, not multicentric, diagnostic criteria not described             | 50          | 48 | 10 | 24 | 8   |
| Bohnet43         | Brazil    | 27.9             | Both         | Outpatient and inpatient, not multicentric, Addiction Severity Index       | 200         | 25 | 17 | 8  | 8   |
| Masferrer36      | Spain     | 45.5             | Male         | Inpatient, not multicentric, DSM-IV-TR                                    | 129         | 72 | 87 |    |     |
| Walter47         | United States | 42.5             | Male         | Inpatient, not multicentric, DSM-IV-TR                                    | 129         | 72 | 87 |    |     |
| de Souza48       | Brazil    | 28.3             | Both         | Inpatient, not multicentric, DSM-IV-TR                                    | 160         | 110| 50 | 49 | 8   |
| Silva39          | Brazil    | 29.8             | Both         | Inpatient, not multicentric, DSM-IV-TR                                    | 160         | 110| 50 | 49 | 8   |
| Gonzi40          | Spain     | 37.3             | Male         | Treatment seeking, inpatient and outpatient, DSM-IV-TR                   | 160         | 110| 50 | 49 | 8   |

Data presented as n.

N/A = not available; NOS = Newcastle-Ottawa Statement; NS = no suicidality; SA = suicide attempt; SI = suicidal ideation.

Discussion

Our findings indicate that there is a high prevalence of SI and SA among cocaine users who access health services: ranging from 27.71 to 43.59%. Similarly, a nationally representative household survey in Brazil detected a 40% and 20.8% prevalence of SI and SA, respectively, in a population of young adult and adult crack users.43 However, a U.S. street outreach study found higher rates among female African American cocaine users, 32% of whom reported at least one lifetime SA.44

In clinical samples of individuals who use psychoactive substances, the prevalence of SI ranges from 17.4 to 49.5%, while SA ranges from 20 to 39%.45,46 A recent study observed that the prevalence of SI and SA was 26 and 34.6%, respectively, for crack users and 15.1 and 28.3%, respectively, for alcohol users.47 In non-clinical samples, the lifetime prevalence of SA in alcohol dependent individuals is about 40%.48 Other psychoactive substances are also associated with suicidal behavior. The prevalence of SI and SA among heroin users ranges from 13 to 34.2% and 9.5 to 40%, respectively.49-53 Another study found that the SA rate among non-institutionalized adolescent ecstasy users in the USA is identical to that of other drug addicts.54 The prevalence of SA and SI is slightly lower among marijuana users (16.5 and 31.5%, respectively).55 Taken together, these high prevalence rates indicate that SI and SA should be addressed in both clinical and home-based studies in this population.

In fact, individuals with suicidal thoughts, attempts, or plans have a greater predisposition to commit suicide than those who have never had them.56,57 This is especially relevant since alcohol is consumed by 43% of the global population.58 54.1% of the population in the respective.49-53 Another study found that the SA rate among non-institutionalized adolescent ecstasy users in the USA is identical to that of other drug addicts.54 The prevalence of SA and SI is slightly lower among marijuana users (16.5 and 31.5%, respectively).55 Taken together, these high prevalence rates indicate that SI and SA should be addressed in both clinical and home-based studies in this population.

In fact, individuals with suicidal thoughts, attempts, or plans have a greater predisposition to commit suicide than those who have never had them.56,57 This is especially relevant since alcohol is consumed by 43% of the global population.58 54.1% of the population in the
The prevalence is similar for marijuana (7.7%), the most consumed illicit drug, followed by cocaine (3.1%), and crack (0.3%) (III Levantamento Domiciliar Sobre o Uso de Drogas Psicotrópicas no Brasil [III LNUD]).

In non-clinical and general populations, studies around the world have found a wide variation in SA prevalence, ranging from 7 to 20.3%, with a SI prevalence ranging from 2.3 to 24.66%. Higher estimates have been found in clinical samples, particularly in individuals with at least one psychiatric disorder. For instance, in individuals with major depressive disorder, the SI and SA prevalence is 37.1% and 24%, respectively. These rates are slightly lower than those observed in cocaine users. In individuals with other mental disorders, such as bipolar affective disorder, the prevalence of SI is very high (61%), although SA is lower (20%).

In patients with post-traumatic stress disorder (PTSD), SI and SA rates of 38.3% and 9.6%, respectively, were found. Therefore, cocaine users have higher rates of suicidal behavior than PTSD patients. In addition, according to psychological autopsy reports, the prevalence of mental disorders among individuals with suicidal behavior was 69.6% in East Asia, 88.2% in North America, and 90.4% in South Asia.
These rates are higher than those of the cocaine users in our meta-analysis.

A systematic analysis from the Global Burden of Disease Study that used suicide mortality data between 1990 and 2016 found a 6.7% increase in the number of suicide deaths, being one of the main causes worldwide of life-years lost. Another review of cohort studies found that psychoactive substance users have a 10 to 20 times greater risk of death by suicide than non-users. Most of those deaths involve heavy use of alcohol, opiates, or amphetamines. In addition, a meta-analysis found a 41% prevalence of suicidal behavior among older adults with a substance use disorder. In a sample from England and Wales, cocaine use was also associated with 8.4% of deaths by self-injury. About 20% of the drug overdose deaths in the United States involve cocaine use. Suicidality and substance use increases the burden on mental health services, and have relevant social and economic consequences. A recent study with young people found that substance use and SA increase the risk of hospitalization. In particular, cocaine users are often stigmatized and risk neglect in medical and psychiatric care. Since a SA is the expression of suicidal thoughts or impulses, it is visible to professionals when a patient seeks health services. On the other hand, suicidal ideation, which was quite prevalent in the findings, is less visible: health professionals must actively search for it. These data show that the most vulnerable subjects must be identified early and offered personalized care, which will help prevent health system overload. A specific instrument or protocol that is short and user-friendly would be a good way to standardize symptom screening in substance users.

Our analyses revealed high heterogeneity among the studies regarding the prevalence of suicidal behavior. To explain this phenomenon, subgroup analyses were conducted for potentially related factors. However, neither age, sex, multicenter study design, treatment regimen, or study quality were the source of this heterogeneity (except for study quality and SA prevalence). Other characteristics associated with suicidal behavior, such as mental disorders, family support, early trauma, and impulsiveness, might help explain these results. One systematic review identified social factors related to SAs, which included conflict, marital and economic problems, and educational failures. However, it should be pointed out that most studies do not provide information about the other characteristics of these individuals, hampering deeper analyses that consider the joint influence of various factors on suicidal behavior.

Our review has other limitations. Most of the included studies were cross-sectional, so cause-and-effect relationships cannot be established. Cohort and longitudinal studies are needed for more robust conclusions about whether cocaine use directly influences suicide risk or if there is a dose-response relation between cocaine use and suicide. Moreover, since our goal was to assess the SI and SA prevalence among clinical populations of cocaine users, generalizations to non-clinical samples should be approached with caution. Despite these limitations, this systematic review and meta-analysis has some strengths: a broad search strategy was applied, and several databases were analyzed to increase search sensitivity and include the largest possible number of studies. In addition, most of the studies had good methodological quality, which allowed us to calculate the prevalence of the intended outcomes. Subgroup analysis was performed, when possible, to minimize bias.

This is the first systematic review with meta-analysis to evaluate suicidal behavior in a clinical population of cocaine users, among whom a high prevalence of SI and SA were observed. Due to these troubling findings in

| Table 2 Subgroup analysis |
|---------------------------|
|                          |
| n (%) | 95%CI | p-value | \(i^2\) (%) |
| Suicidal ideation subgroups |
| Multicenter |
| Yes  | 9 (43.11) | 28.62-58.88 | 0.48 | 95 |
| No   | 1 (49.05)  | 43.98-54.14 | N/A |
| Treatment regimen |
| Outpatient | 3 (55.39) | 18.29-87.32 | 0.56 | 97 |
| Inpatient  | 4 (45.78) | 28.89-63.71 | 91 |
| Both    | 3 (33.06) | 16.02-56.11 | 95 |
| Study quality |
| High   | 7 (50.69) | 36.16-65.10 | 0.09 | 94 |
| Low    | 3 (28.06) | 13.33-49.71 | 91 |
| Suicide attempt subgroups |
| Multicenter |
| Yes  | 2 (26.87) | 24.67-29.19 | 0.81 | 92 |
| No   | 10 (27.92) | 20.53-36.74 | 48 |
| Treatment regimen |
| Outpatient | 5 (27.14) | 20.33-35.21 | 0.52 | 79 |
| Inpatient  | 4 (33.28) | 17.50-53.97 | 95 |
| Both    | 3 (23.12) | 16.65-31.17 | 84 |
| Study quality |
| High   | 9 (31.00) | 24.16-38.80 | 0.03 | 93 |
| Low    | 3 (18.48) | 11.73-27.89 | 74 |

95%CI = 95% confidence interval; \(i^2\) = I-square statistic; N/A = not available.
this vulnerable population, which are compounded by underestimation or underassessment, clinicians and even mental health professionals need greater awareness and training. Thus, it is relevant to include this condition in the development of public health policies, especially prevention strategies for this severe problem.

Acknowledgements
The authors wish to thank the Coordenação de Pergaminho do Pessoal de Nível Superior (CAPES/PEC-FG-025/2018, finance code 001).

Disclosure
The authors report no conflicts of interest.

References
1 World Health Organization (WHO). Preventing suicide: a global imperative. Geneva: WHO; 2014.
2 World Health Organization (WHO). Suicide [Internet]. 2021 Jun 17 [cited 2022 Feb 7]. www.who.int/news-room/fact-sheets/detail/suicide www.who.int/mental_health/prevention/suicide.
3 Borges G, Nock MK, Abad JM, Hwang I, Sampson NA, Alonso J, et al. Twelve-month prevalence of and risk factors for suicide attempts in the World Health Organization world mental health surveys. J Clin Psychiatry. 2010;71:1617-28.
4 Bastos LF, https://www.facebook.com/pahowho.Organizacao Pan-americana de Saude (OPAS), Organizao Mundial da Saude (OMS). Folha informativa: Suicidio [Internet]. [cited 2022 Feb 07]. www.paho.org/pt/topics/suicidio.
5 Corrêa H, Barrero SP. Suicidio: uma morte evitável. são Paulo: Atheneu; 2006.
6 Silverman MM. The language of suicidology. Suicide Life Threat Behav. 2006;36:519-32.
7 Botega NJ, Barros MB, de Oliveira HB, Dalgalarrondo P, Marin-León L. Suicidal behavior in the community: prevalence and factors associated with suicidal ideation. Braz J Psychiatry. 2005;27:45-53.
8 Turecki G, Brent DA. Suicide and suicidal behaviour. Lancet. 2016;387:1227-39.
9 Franklin JC, Ribeiro JD, Fox KR, Bentley KH, Kleiman EM, Huang X, et al. Risk factors for suicidal thoughts and behaviors: a meta-analysis of 50 years of research. Psychol Bull. 2017;143:187-232.
10 Breet E, Goldstone D, Bantjes J. Substance use and suicidal ideation. Braz J Psychiatry. 2005;27:45-53.
11 Marzuk PM, Tardiff K, Leon AC, Stajic M, Morgan EB, Mann JJ. Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period. Am J Psychiatry. 1992;149:371-5.
12 Karch DL, Barker L, Strine TW. Race/ethnicity, substance abuse, and mental illness among suicide victims in 13 US states: 2004 data from the National Violent Death Reporting System. Inj Prev. 2006;12 Suppl 2: ii2-7.
13 Ryb GE, Cooper CC, Dischinger PC, Kufera JA, Auman KM, Soderstrom CA. Suicides, homicides, and unintentional injury deaths after trauma center discharge: cocaine use as a risk factor. J Trauma. 2009;67:490-6.
14 Narvaez JC, Jansen K, Pinheiro RT, Kapczinski F, Silva RA, Pechansky F, et al. Psychiatric and substance-use comorbidities associated with lifetime crack cocaine use in young adults in the general population. Compr Psychiatry. 2014;55:1369-76.
15 Paim Kessler FH, Barbosa Terra M, Faller S, Ravy Stolf A, Carolina Peuker A, Benzano D, et al. Crack users show high rates of antisocial personality disorder, engagement in illegal activities and other psychosocial problems. Am J Addict. 2012;21:370-80.
16 Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
17 Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019.
18 Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. [cited 2020 Jul 24]. www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19 Shuster JJ. Review: Cochrane handbook for systematic reviews for interventions: version 5.1.0, update Mar 2011. Res Synthesis Methods. 2011;201:126-30.
20 Higgins JP, Thompson DG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
21 Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1-48.
22 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A, Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
23 Lowenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, Simon RP. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med. 1987;83:841-6.
24 Rich JA, Singer DE. Cocaine-related symptoms in patients presenting to an urban emergency department. Ann Emerg Med. 1991;20:616-21.
25 Marzuk PM, Tardiff K, Leon AC, Stajic M, Morgan EB, Mann JJ. Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period. Am J Psychiatry. 1992;149:371-5.
26 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A, Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
27 Lowenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, Simon RP. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med. 1987;83:841-6.
28 Roy A. Childhood trauma and suicidal behavior in male cocaine dependent patients. Suicide Life Threat Behav. 2001;31:194-6.
29 Ilgen MA, Harris AH, Moos RH, Tiet QQ. Predictors of a suicide attempt one year after entry into substance use disorder treatment. Alcohol Clin Exp Res. 2007;31:635-42.
30 Zubaran C, Foresti K, Thorell MR, Franceschini P, Homero W. Depressive symptoms in crack and inhalant users in Southern Brazil. J Ethn Subst Abuse. 2010;9:221-36.
31 Bohrert AS, Koerder KM, Ilgen MA. Suicide attempts and overdoses among adults entering addiction treatment: comparing correlates in a US National Study. Drug Alcohol Depend. 2011;119:106-12.
32 Serfaty E, Desouches A, Bartoli CG, Rivera LE, Masutinis A. Consum of taboo drug, alcohol, drogas y su relacion con los intentos de suicidio en poblacion asistida en la guardia de un hospital general polivalente. Psicofarmacol B Aires. 2011;11:9-19.
33 de Souza AM, de Melo Miranda MP, de Moura Souza E, Sartes LM, de Miranda CT. Ideacao suicida e tentativa de suicidio entre usuarios de crack. Rev Bras Pesq Saude. 2014;16:115-21.
34 Masferrer L, Garre-Olmo J, Carapós B. Risk of suicide: its occurrence and related variables among bereaved substance users. J Subst Use. 2016;21:191-7.
35 Walter KN, Petry NM. Lifetime suicide attempt history, quality of life, and objective functioning among HIV/AIDS patients with alcohol and illicit substance use disorders. Int J STD AIDS. 2016;27:476-85.
36 Arias SA, Dumas O, Sullivan AF, Boudreaux ED, Miller I, Camargo CA Jr. Substance use as a mediator of the association between demographics, suicide attempt history, and future suicide attempts in emergency department patients. Crisis. 2016;37:385-91.
37 da Silva DC, de Ávila AC, Yates MB, Cazassa MJ, Dias FB, Souza MH de, et al. Sintomas psiquiatricos e caracteristicas sociodemograficos associados a tentativa de suicidio de usuarios de cocaína e crack em tratamento. J Bras Psiquiatr. 2017;66:89-95.
38 López-Górrara JJ, Fernández-Montalvo J, Arteaga A, Haro B. Suicidal ideation and attempts in patients who seek treatment for substance use disorder. Psychiatry Res. 2018;269:542-8.
39 Roglio VS, Borges EN, Rabelo-da-Ponte FD, Orbeli F, Scharner JN, Schuch JB, et al. Prediction of attempted suicide in men and women with crack-cocaine use disorder in Brazil. PLoS One. 2020;15:e0232242.
